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Abstract
The increasing observation of mutual exclusivity correlations among cancer gene mutations is
a key component for identifying driver events or pathways in cancer genome analysis. Here we
report a rigorous statistical method to compute an exact p-value for the beyond-pairwise mutual
exclusivity or co-occurrence relationships among cancer gene mutations by enumerating a null dis-
tribution of overlapping mutations across more than two genes. The validity and the advantage of
our method is explicitly demonstrated in both cancer gene mutations and simulation data through
the comparison to the permutation test.
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I. INTRODUCTION
The recent development of high-throughput genome sequencing technologies reveals a re-
markable complexity in genetic and epigenetic aberrations characteristic of cancer initiation
and progression [1, 2]. Given genetic heterogeneities across samples even in a single cancer
type one of challenges is to distinguish underlying driver events from a myriad of random
passenger events [3, 4]. The standard approach for discovering cancer driver genes is to
identify genes with a significantly higher mutation rate across samples than the background
mutation rate [5]. In addition to the mutational recurrence across samples the recent cancer
gene discovery is often corroborated by evaluating a significance of individual mutations or
genes in the context of mutation patterns projected onto cellular signaling and regulatory
pathways [6]. The mutual exclusivity relationship is commonly observed among driver mu-
tations on the same pathway and plays an important role in discovering cancer driver events
or pathways in many network and pathway analysis algorithms [7–9].
Fisher’s exact method [10] or hypergeometric test provides an exact p-value for the pair-
wise mutual exclusivity in two genes by directly enumerating more extreme cases with over-
lapping mutations equal or less than the observed one. However, it is non-trivial to extend
the pairwise exact test to the gene set consisting of more than two genes. Considering an
illuminating role of mutation patterns in the discovery of cancer driver genes or pathways
it is very demanding to develop a systematic method to evaluate a statistical significance
of the beyond-pairwise correlations or anti-correlation among mutations. In this paper, we
report a rigorous statistical method to determine an exact p-value for the beyond-pairwise
mutual exclusivity or co-occurrence relationships among cancer mutations in an arbitrary
number of genes. Our study illustrates that a null distribution of overlapping mutations
across genes can be determined via a sequential operation of a hypergeometric sampling and
the exact p-value can be computed through a simple recursive formula for given mutation
data. We validated our method in both cancer gene mutations and simulation data through
the comparison to the permutation test.
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II. METHODS
Let us start by briefly reviewing the pairwise mutual exclusivity, in which two genes g1
and g2 had n1 and n2 mutations, respectively, across n samples. When n1 mutations in g1 are
randomly chosen from n samples, and another random samples lead to n2 mutations in g2,
the probability that two genes have z overlapping mutations exactly follows a hypergeometric
distribution for z ∈ [max(0, n1 + n2 − n),min(n1, n2)] as
P2(z) = H(z;n1, n− n1, n2) =
(
n1
z
)(
n−n1
n2−z
)(
n
n2
) , (1)
(
n
m
)
being a binomial coefficient. The distribution P2(z) describes a hypergeometric sampling
characterized by the probability of choosing z white balls in n2 draws without replacements
from a finite population of n1 white balls and (n−n1) black balls. The p-value for the pairwise
exclusivity is determined by summing all probabilities of more extreme cases with z ≤ z0, z0
being the observed overlapping mutations, as
∑z0
z=z∗ P2(z), z
∗ = max(0, n1 + n2 − n). The
hypergeometric test with Eq. (1) is identical to the one tailed version of Fisher’s exact test.
The mutation data for m genes with each ni mutations (i = 1, . . . ,m) across n samples
can be represented by n × m binary matrix A, Aij = 1 if gene gj is mutated in sample
i, and 0 otherwise. Here we quantified the overlapping mutations by z = Γ(A) − ω(A),
Γ(A) =
∑
ij Aij and ω(A) =
∑
i max(Ai1, . . . , Aim). Note that ω(A) represents the number
of samples having at least one mutation across genes and z (≥ 0) becomes zero only if
mutations among genes are perfectly exclusive.
Our goal is to construct a random null distribution characterized by the probability that
the set of m genes (m ≥ 3) have z overlapping mutations. For this purpose we first consider
the simplest case of m = 3. Without a loss of generality we assume n1 ≥ n2 ≥ n3 by
re-ordering genes. Since the probability for x overlapping mutations between g1 and g2 is
already determined as H(x;n1, n−n1, n2) the remaining step is to enumerate newly formed
overlapping mutations with an addition of g3 for the fixed overlaps x between g1 and g2. The
key finding is that the probability that all three genes have extra y overlapping mutations
in addition to x is also determined by a hypergeometric sampling, yielding H(y; p, q, n3) for
y ∈ [max(0, p+n3−n),min(p, n3)], p = max(n1 +n2− x, n) and q = n− p. In analogous to
the pairwise mutual exclusivity, this distribution describes a likelihood of choosing y white
balls in n3 draws without replacements from a finite population of n size comprised of p
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FIG. 1: Mutations in KRAS, STK11, and EGFR in lung adenocarcinoma project [11]
white balls and q black balls. Note that the number of white balls is now (n1 + n2 − x) due
to existing x overlapping mutations between g1 and g2.
Summing probabilities for all possible choices of x and y the final null distribution of
observing z overlapping mutations is obtained as
P3(z) =
n2∑
x=x∗
n3∑
y=y∗
P2(x)H(y; p, q, n3)δ [z − (x+ y)] (2)
x∗ = max(0, n1 + n2 − n), y∗ = max(0, n1 + n2 + n3 − n), p = max(n1 + n2 − x, n), and
q = n − p. For an arbitrary m (≥ 3) Pm(z) is iteratively determined using a following
recursive relation,
Pm(z) =
n∗m∑
x=x∗
nm∑
y=y∗
Pm−1(x)H(y; p, q, nm)δ [z − (x+ y)] (3)
where x∗ = max(0, n1 + n∗m − n), y∗ = max(0, n1 + n∗m + nm), p = max(n1 + n∗m − x, n) and
q = n− p. Here n∗m =
∑m−1
j=2 nj denotes the number of maximum overlapping mutations in
the gene set consisting of g1, . . . , gm−1.
III. RESULTS
We validated our method in the mutation data of three driver genes, KRAS, STK11,
and EGFR, in the lung adenocarcinoma sequencing project [11]. This gene set was iden-
tified as the most exclusive one for m = 3 by DENDRIX analysis [9]. The mutation data
across 163 samples is represented in Fig. 1, resulting in n1 = 60, n2 = 34, n3 = 30, and
z0 = 14. In Fig. 2(a), the exact null distribution P3(z) from Eq. (3) is compared with the
approximate P˜3(z;Np) determined from the permutation test with varying Np, Np being
the number of permutations. Note that P˜3(z,Np) is only non-zero in a narrow dynamic
region z corresponding to [zl, zu], P3(zl,u) ∼ 1/Np, while P3(z) spans a full dynamic range
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FIG. 2: (a) The exact null distribution Log[P3(z)] of Eq. (3) and approximate Log[P˜3(z,Np)] from
the permutation test with varying Np as a function of overlapping mutations z for the gene set,
KRAS, STK11, and EGFR, in lung adenocarcinoma project [11], and (b) p-values as a function of
Np. The vertical and horizontal dashed lines corresponds to z0 and the exact p-value, respectively.
of z ∈ [max(0,∑mi ni − n),max(0,∑mi=2 ni)] = [0, 64]. The p-value from the permutation
test in Fig. 2(b) asymptotically converges to the exact p = 1.673 × 10−5 with increasing
Np, but p-values are zero for small Np since the exact p-value < 1/Np. We also tested
our method in a more complicated case with n = 500 and m = 5 using a simulation data
(see Supplementary Figure and text for details). Finally, we would like to stress that our
method is equally applicable to the significance test of co-occurring mutations by summing
probabilities of more extreme cases with z ≥ z0, yielding p-value =
∑
z≥z0 Pm(z).
IV. SUMMARY
In summary, a rigorous statistical method to evaluate a significance of beyond-pairwise
mutual correlations among mutation data is developed by establishing an exact null distri-
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bution of overlapping mutations across genes. In contrast to the permutation test, which
is approximate and computationally demanding with increasing m, our method enables an
instant calculation of exact p-values regardless of the size of interesting gene set, making
our method well-suited to an extensive search or prioritizing driver events or pathways in
heterogeneous mutation data combined with other network or pathway analysis algorithms.
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Simulation Data
To validate our method in a more complicated situation we created a following simulated
mutation data with n = 500 and m = 5 characterized by
Aij =

1 if i ∈ [1, 200] for j = 1,
1 if i ∈ [101, 250] for j = 2,
1 if i ∈ [201, 300] for j = 3,
1 if i ∈ [351, 450] for j = 4,
1 if i ∈ [431, 480] for j = 5,
0 otherwise,
(4)
n1 = 200, n2 = 150, n3 = 100, n4 = 100, n5 = 50, and z0 = 170. In Eq. (4), non-zero
elements of Aij for each j could be assigned to any samples under the constraints of ni and
the number of overlapping mutations in each pair of genes, and the final null distribution
and corresponding p-value are not affected by those permutations.
The exact null distribution P5(z) was compared in Fig. 3(a) with approximate ones
P˜5(z,Np) at various Np, indicating that more than 10
6 random permutations are needed
to provide a fair comparison around z ∼ z¯, z¯ being the mean overlapping mutation, as ver-
ified in relative errors in Fig. 3(b). However, as clearly seen in Fig. 3(b), P˜5(z,Np) provides
approximate probabilities in a narrow dynamic region of z ∈ [zl, zu], P5(zl,u) ∼ 1/Np, in
comparison to P5(z) spanning a full dynamic range of z ∈ [100, 400]. As expected, the per-
mutation test failed to provide any significance measure for the exclusivity since the correct
p-value of 8.134 × 10−16 is far less than the minimum resolution 1/Np in the permutation
test.
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FIG. 3: (a) The exact null distribution P5(z) and approximate distributions P˜5(z,Np) from the per-
mutation test with varying Np from 10
4 to 106 as a function of overlapping mutations z for the simu-
lation data in Eq. (4) with n = 500 andm = 5, (b) relative errors E(z) = |(P5(z)−P˜5(z,Np))/P5(z)|
at non-zero P˜5(z,Np), and (c) Log[P5(z)] (solid line) and Log[P˜5(z, 10
6)] (diamonds). Only non-
zero values of P˜5(z, 10
6) were shown and the dashed line corresponds to z0 in (c).
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